Alpha radiation therapy

Oncoinvent focuses on a technology platform that uses radionuclides to deliver powerful alpha radiation directly to cancer cells, killing them through causing irreparable DNA damage.

Alpha radiation, or alpha particles, are known for their high energy and short path-length in comparison to other radiation modalities such as traditional external beam radiation therapy and beta radiation. When a cancer cell is hit by alpha particles, its DNA will be damaged in a highly complex manner. This type of DNA damage with many of the so-called “double-stranded DNA breakages” is very difficult to repair for the cancer cell. As a result, there is a high probability that the cancer cell dies when hit by alpha particles, even for cancers that are resistant to chemotherapy and external beam therapy. At the same time, the less than 0.1 mm range of alpha particles minimizes radiation exposure to surrounding healthy tissues and cells.

Alpha radiation can be harnessed from certain radioactive elements, i.e., radionuclides. These “alpha emitters” can be used as radioactive payloads in cancer medicines (radiopharmaceuticals). The medicines are administered to the patient for internal irradiation of the cancer. One way to ensure cancer-directed cell killing is by coupling these radionuclides to delivery vehicles or targeting molecules.

Radspherin®

Oncoinvents lead product candidate is designed to treat cancer in the peritoneal cavity

Description of the product

  • Inorganic microparticles as carriers of alpha-emitters
  • High-power radiation with a short range
  • Short half-life of the radionuclide
  • Microparticles which degrade slowly in the body
  • Regional retention of effective radiation dose

See Expanded Access Policy

About

Management

Board of Directors

Radspherin®

Pipeline

Publications

News

Events

Newsletter subscription

Reports and presentations

The Share

IR Contact

+47 22 18 33 05

Oncoinvent ASA Gullhaugveien 7 0484 Oslo Norway

© Oncoinvent. All rights reserved. Design by Anagram Design AS

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close